General MedicationsORALStandard
AYVAKIT
AVAPRITINIB
Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview AYVAKIT is listed in Drugs@FDA under application 212608 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient AVAPRITINIB Form and strength TABLET;ORAL - 300MG Sponsor BLUEPRINT MEDICINES Submission history Latest submission status date: 2024-11-08 00:00:00.
Structured Monograph
Clinical summary
Approval overview AYVAKIT is listed in Drugs@FDA under application 212608 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AVAPRITINIB Form and strength TABLET;ORAL - 300MG Sponsor BLUEPRINT MEDICINES Submission history Latest submission status date: 2024-11-08 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.